Stockscreener 앱 받기
1,149.36
0.88%
-10.24
시간 외 거래:
1146.65
-2.71
-0.24%
전일 마감가:
$1,159.60
열려 있는:
$1150.61
하루 거래량:
2.16M
Relative Volume:
0.73
시가총액:
$1.02T
수익:
$72.25B
순이익/손실:
$25.28B
주가수익비율:
41.37
EPS:
27.781
순현금흐름:
$10.37B
1주 성능:
-2.15%
1개월 성능:
+3.02%
6개월 성능:
+14.53%
1년 성능:
+54.71%
1일 변동 폭
$1,138.31
$1,158.44
1주일 범위
$1,137.50
$1,188.33
52주 변동 폭
$712.05
$1,292.65
일라이 릴리 Stock (LLY) Company Profile
명칭
Lilly Eli Co
전화
(317) 276-2000
주소
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,149.36 | 1.11T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
275.23 | 644.33B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
256.46 | 462.68B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
150.33 | 367.58B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
159.99 | 296.97B | 54.66B | 13.58B | 16.05B | 7.0171 |
일라이 릴리 Stock (LLY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-17 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2026-02-25 | 개시 | RBC Capital Mkts | Outperform |
| 2026-02-20 | 개시 | Barclays | Overweight |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-12-16 | 업그레이드 | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | 재확인 | BofA Securities | Buy |
| 2025-12-15 | 재확인 | Goldman | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-11-10 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | 재확인 | BMO Capital Markets | Outperform |
| 2025-10-14 | 업그레이드 | Erste Group | Hold → Buy |
| 2025-09-17 | 다운그레이드 | Berenberg | Buy → Hold |
| 2025-08-27 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2025-08-18 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | 다운그레이드 | Erste Group | Buy → Hold |
| 2025-04-28 | 다운그레이드 | HSBC Securities | Buy → Reduce |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-09-13 | 재개 | Citigroup | Buy |
| 2024-08-12 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-02-21 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2024-02-16 | 재확인 | Morgan Stanley | Overweight |
| 2023-12-21 | 다운그레이드 | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-20 | 재개 | UBS | Buy |
| 2023-08-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-26 | 재확인 | Citigroup | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-05-24 | 재확인 | BofA Securities | Buy |
| 2023-05-24 | 재확인 | UBS | Buy |
| 2023-03-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-15 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-09-22 | 업그레이드 | UBS | Neutral → Buy |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-03-10 | 개시 | Daiwa Securities | Outperform |
| 2022-01-21 | 업그레이드 | DZ Bank | Hold → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-16 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-16 | 재확인 | BofA Securities | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-10-11 | 업그레이드 | Berenberg | Hold → Buy |
| 2021-09-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-05 | 업그레이드 | DZ Bank | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-06-24 | 재확인 | Cantor Fitzgerald | Overweight |
| 2021-01-19 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-12-10 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-09-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2019-12-18 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-04-24 | 업그레이드 | Edward Jones | Hold → Buy |
| 2019-04-11 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-03-12 | 개시 | JP Morgan | Overweight |
| 2019-01-23 | 개시 | UBS | Buy |
| 2018-11-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2018-10-31 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-10-01 | 재확인 | SunTrust | Buy |
| 2018-09-26 | 재개 | JP Morgan | Overweight |
모두보기
일라이 릴리 주식(LLY)의 최신 뉴스
Novo Nordisk: The Pill That Could Close The Gap With Lilly (NYSE:NVO) - Seeking Alpha
The Oral GLP-1 Tracker: Novo's Wegovy pill back on track as Lilly's momentum slows - Fierce Pharma
Here’s How Much You Would Have Made Owning Eli Lilly Stock In The Last 5 Years - Benzinga
Eli Lilly and Company (NYSE:LLY) Shares Up 1%Here's What Happened - MarketBeat
Bristol-Myers Squibb (BMY) Bets $2.3 Billion on Texas While Eli Lilly (LLY) Wins in the UK - Yahoo Finance
Eli Lilly will replace lost insulin after Indiana storms - nwitimes.com
Amplitude Therapeutics and Lilly Partner to Advance Trans-Amplifying RNA Vaccine Platform for Infectious Disease - BioPharm International
Stock Split Watch: Is Eli Lilly (LLY) Stock Next? - The Motley Fool
Lilly to work with Boston-based firm to develop RNA vaccine platform - dailyjournal.net
Roundup: Amplitude Therapeutics, Chai Discovery Enter Collaborations with Eli Lilly, Bristol Myers Squibb - Pharmaceutical Executive
Eli Lilly (NYSE:LLY) Shows Strong Growth and a Compelling Technical Setup - ChartMill
How cost and perception could reshape the GLP-1 market - BioPharma Dive
Eli Lilly and Company $LLY Shares Acquired by Kelleher Financial Advisors - MarketBeat
Private Advisory Group LLC Purchases 2,056 Shares of Eli Lilly and Company $LLY - MarketBeat
M3 Wealth Management LLC Purchases Shares of 2,836 Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Stock Holdings Decreased by SMART Wealth LLC - MarketBeat
Russell Investments Group Ltd. Has $942.43 Million Stake in Eli Lilly and Company $LLY - MarketBeat
Focus Partners Advisor Solutions LLC Has $16.78 Million Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
3,643 Shares in Eli Lilly and Company $LLY Purchased by Bellars Harris Wealth Management LLC - MarketBeat
ABN AMRO Bank N.V. Reduces Stock Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company (NYSE:LLY) Stock Price Down 2.6%Time to Sell? - MarketBeat
There’s a Black Market for Eli Lilly’s Unapproved GLP-1 Drug. Here’s Why That’s Bullish - The Motley Fool
Eli Lilly reveals plans for Lehigh Valley construction to avoid traffic problems. Here are the details. - The Morning Call
Eli Lilly Revenue Jumps 48% as Mounjaro and Zepbound Sales Reach $14.9B - TradingKey
Eli Lilly: New type 2 diabetes jab could slash number of injections to one a week - The Independent
Eli Lilly and Company $LLY Stock Position Raised by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
Mosaic Family Wealth Partners LLC Grows Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY is Donaldson Capital Management LLC's 7th Largest Position - MarketBeat
Canton Hathaway LLC Has $1.05 Million Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Bought by AlTi Global Inc. - MarketBeat
Upper Macungie planners endorse Eli Lilly plan for manufacturing campus - WFMZ.com
Eli Lilly Price Forecast: The Next Big Stock After Weight-Loss Drug Breakthrough? - Mitrade
Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race? - Yahoo Finance
Eli Lilly and Company (NYSE:LLY) Trading 4.5% HigherHere's Why - MarketBeat
Eli Lilly and Co (LLY) Stock Up 4.5% and Still Undervalued -- GF Score: 96/100 - GuruFocus
Could Eli Lilly Be Worth More Than SpaceX by the End of 2026? - Yahoo Finance
LLY Looks 15.4% Undervalued on GF Value™ Amid New Vaccine Partne - GuruFocus
Amplitude Therapeutics and Lilly Enter Strategic Collaboration to Develop Trans-Amplifying RNA Vaccines for Infectious Diseases - PR Newswire
Eli Lilly Shares Approach High as 60% Volume Surge Offsets 13% Price Fall - TechStock²
Eli Lilly hits $1 trillion valuation, with stro... - Pluang
Eli Lilly, Novo Nordisk and Merck: Buy, Sell or Hold? - 24/7 Wall St.
Lilly Stock Rises on Alzheimer Deal: Retatrutide Moat Still Not Fully Priced - Tech Times
How Does LLY's Q2 GLP-1 Portfolio Performance Stack Up Against NVO's? - TradingView
Stock Forecast: The Market is Sleeping on Eli Lilly’s Next $1 Trillion Opportunity - 24/7 Wall St.
Eli Lilly and Company (NYSE:LLY) Reaches New 12-Month HighStill a Buy? - MarketBeat
Eli Lilly and Co Stock (LLY) Moved Up by 5.18% on Aug 19: What Investors Need To Know - TradingKey
Eli Lilly (NYSE:LLY): Is Its Valuation Story Getting Stronger? - Kalkine Media
Eli Lilly stock hits all-time high at 1249.95 USD By Investing.com - Investing.com Nigeria
Why is Eli Lilly stock surging today? - Investing.com
Lilly Turns Lifelong Struggle with Weight Into Story of Hope in ‘A Life Covered’ - Little Black Book | LBBOnline
Inside Eli Lilly’s Pre-Launch Push to Police the Retatrutide Market - thefashionlaw.com
일라이 릴리 (LLY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.15%
자본화:
|
볼륨(24시간):